The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2.
Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...
Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated an overall response rate of... No ads & unlimited access to all current ...
Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...
1. Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...
1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the ...
1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug conjugate (ADC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback